[This review was originally posted at the Nieman Journalism Lab Purchase Glucophage, on July 18, 2011.]

News Corp.'s scandal keeps growing: Rupert Murdoch might have hoped News Corp.'s phone hacking scandal would die down when he closed the British tabloid News of the World last week, but it only served to fuel the issue's explosion. This past week, the scandal's collateral damage spread to News Corp.'s proposed takeover of the British broadcaster BSkyB: Faced with increasing pressure from the British government and the revelation that News Corp. journalists tried to get private records of former Prime Minister Gordon Brown, News Corp. dropped the BSkyB bid, which had been a huge part of the company's U.K. strategy. Buy no prescription Glucophage online, Plenty of other problems are cropping up for News Corp., too. The top lawyer for its U.K, Purchase Glucophage. newspaper branch, News International, quit. The company's stock lost $7 billion in four business days at one point. A pre-existing U.S. shareholders' suit expanded to cover the hacking scandal, is Glucophage addictive. The Murdochs have to testify before British Parliament Purchase Glucophage, this week about the scandal, and the FBI started investigating U.S.-related aspects of the issue. That's all in addition to the ongoing problems News Corp. faces, as detailed by Poynter's Rick Edmonds.

The scandal has led quite a few writers to criticize the culture that Murdoch has created at News Corp. Capital New York's Tom McGeveran and Reuters' John Lloyd railed on Murdoch and News Corp.'s character, Carl Bernstein called this Murdoch's Watergate, Canada, mexico, india, and the Observer's editorial board called for systemic reforms in Britain so Murdoch's influence can never be so strong. Members of the Bancroft family said they wouldn't have sold the Wall Street Journal to Murdoch in 2007 if they'd have known the hacking was going on, Purchase Glucophage.

On the other hand, the New York Times pointed out that sleazy British tabloid tactics are hardly limited to Murdoch, and media critic Howard Kurtz noted that they're very much alive in the U.S. mainstream press, too. New York Times columnist Roger Cohen defended Murdoch, saying he's been good for journalism on the whole, purchase Glucophage online, and Gawker's John Cook defended those tabloid reporting tactics. Meanwhile, j-prof Jeff Jarvis and the Telegraph's Toby Harnden urged the British government not to respond by enacting more regulation. Purchase Glucophage, News Corp.'s retreat might not stop with News of the World and BSkyB. Murdoch biographer Michael Wolff and others have reported that the company's execs are debating whether to get out of Britain's newspaper business entirely, and several observers chimed in to say that might actually make a good deal of business sense. Media analyst Ken Doctor said News International is losing steam, After Glucophage, and the Financial Times' John Gapper said newspapers are becoming far more trouble than they're worth to Murdoch.

Not only that, but the New Yorker's John Cassidy said dropping his U.K. newspapers could let Murdoch revive his BSkyB bid, and Jeff Jarvis speculated that when Murdoch chooses between the power that the papers give him and the money saved by getting rid of them, he'll choose the money. In an interview with the Wall Street Journal, Murdoch called the rumors of a newspaper sell-off "rubbish."

But just because News of the World and News International may be dead and dying, that doesn't mean newspapers as a whole are, argued David Carr of the New York Times, Purchase Glucophage. As he noted, it was the Guardian's dogged reporting that finally broke this story open. Murdoch "prefers his crusades to be built on chronic ridicule and bombast, Glucophage used for. But as The Guardian has shown, the steady accretion of fact — an exercise Mr. Murdoch has historically regarded as bland and elitist — can have a profound effect," Carr wrote. The Atlantic also had praise for the Guardian, and Poynter's Mallary Jean Tenore interviewed one of its editors about the lonely journey of covering the phone hacking story.

—

HuffPo aggregation under the microscope Purchase Glucophage, : A lively discussion about the rights and wrongs of aggregation developed last week out of a column by Ad Age media critic Simon Dumenco, who complained that the Huffington Post had extensively summarized one of his posts, buried the link to the original, and — contrary to Arianna Huffington's argument that her site benefits those they aggregate by sending them readers — gave him just 57 page views. Buy Glucophage without a prescription, The Huffington Post responded by apologizing and suspending the article's writer. HuffPo business editor Peter Goodman told Adweek the piece was a fully formed article when it should have been a simple introduction and a link, but Dumenco responded to the apology by arguing that the writer did nothing out of the ordinary — this is just how HuffPo tells its writers to do it.

Dumenco's point was echoed by several others: The Awl's Choire Sicha said the suspended writer was doing what she was taught, Gawker's Ryan Tate, drawing on a revealing quote from a former HuffPo writer, made the same point: "This is pretty ridiculous, given HuffPo's systematic, Glucophage dosage, officially-sanctioned approach to rewriting too much of people's news articles." British journalist Kevin Anderson called HuffPo's summary-heavy aggregation "a pretty cynical strategy," and paidContent's Staci Kramer said HuffPo needs to respect its sources, rather than treating a link as a favor.

Gabe Rivera, whose news site, Techmeme, Where can i order Glucophage without prescription, was compared to HuffPo favorably by Dumenco, looked for terms to distinguish what his site does from what HuffPo does. Poynter's Julie Moos said some measure of originality will always make for better journalism and a better business model than heavy aggregation, and ZDNet's Tom Foremski pined for the old blogging mentality whose goal was to add value, Purchase Glucophage. In a short podcast, author Steven Rosenbaum said this is a logical time to step back and evaluate exactly what constitutes ethical aggregation.

There were a few dissenters, though: GigaOM's Mathew Ingram and Slate's Jack Shafer both argued that the type of aggregation that HuffPo does has been around for ages in traditional media (especially in Britain, according to Forbes' Tim Worstall). In fact, Glucophage coupon, Shafer said, news orgs could learn a something valuable from the Huffington Post: "That a huge, previously ignored readership out there wants its news hot, quick, and tight."

—

Comparing Google+, Facebook, Cheap Glucophage, and Twitter: It's been just about three weeks since Google+ launched, and Google's new social network is growing like a weed, with estimates of as many as 10 million users so far. (Its number of active users may soon be approaching Twitter's figures.) Google+ news has dominated Twitter, and Google's also working on integrating it with Gmail. Purchase Glucophage, With Plus' incredible growth, tech observers have been going back and forth about what social network Google+ is disrupting most. PCWorld's Megan Geuss wondered whether Google+ and Facebook can coexist, and PC Magazine's John Dvorak posited that all the excitement about Google+ is more or less just pent-up frustration with Facebook. The New York Times' David Pogue and Technology Review's Paul Boutin both compared Google+ favorably to Facebook, largely because of its superior privacy controls (though GigaOM's Mathew Ingram pointed out that it may not be a privacy improvement for some people).

Meanwhile, Search Engine Land's Danny Sullivan said Google+ is more comparable to Twitter, Glucophage natural, then went ahead and made a thorough, smart comparison between the two. The Atlantic's Alexis Madrigal said Google+ might end up being more conversational than Twitter, which he called more of a call-and-response: Google+ "won't be as good at connecting people to information or each other quickly, but it might be better at longer form discussions and whatever we call the process by which people pull reasoned thoughts from their networks into public discourse." Hutch Carpenter said Google+ resembles both Facebook and Twitter, and Computer World's Mike Elgan wrote that it'll disrupt just about everything.

Still, Google+ has its limits: ReadWriteWeb's Marshall Kirkpatrick explained why he'd never move his personal blog there as some are doing, and Instapaper's Marco Arment and the Guardian's Dan Gillmor both urged readers to keep a space for their own online identity outside of spaces like Google+ or Facebook, Purchase Glucophage. For journalists feeling out Google+, Meranda Watling of 10, Glucophage from canada,000 Words put together a preliminary guide.

—

Reading roundup: Here's what else people were talking about this past week:

— The newspaper chain MediaNews made a distinctive play for the tablet news market last week, announcing the launch of TapIn, a location-based news app made specifically for tablets. It'll start in the Bay Area in partnership with the San Jose Mercury News. Ken Doctor, Jeff Sonderman, Glucophage overnight, and Mathew Ingram all wrote about what makes it worth watching.

— The Economist continued running pieces all week in its series on the future of the news industry. You can check out several writers'reasons for optimism or read the opening statements in an ongoing debate between NYU's Jay Rosen and author Nicholas Carr about whether the Internet has been good for journalism.

— Boston Globe developer Andy Boyle made his pitch for young journalists to go into web development, or as he put it, "learn to make the internets."

— Poynter's Jeff Sonderman put together two great social media how-to's for journalists: One on verifying information on social media, and the other on strategies for engagement on Facebook.

— Finally, NYU's Clay Shirky gave us another thoughtful essay on the unbundling of news and why the news ecosystem needs to be chaotic right now. In the end, though, here's what he believes news should be: "News has to be subsidized because society’s truth-tellers can’t be supported by what their work would fetch on the open market"; "news has to be cheap because cheap is where the opportunity is right now"; and "news has to be free, because it has to spread.".

Similar posts: Zoloft No Rx. Bactrim For Sale. Glucophage Price. Tramadol coupon. Glucophage for sale. Cephalexin reviews.
Trackbacks from: Purchase Glucophage. Purchase Glucophage. Purchase Glucophage. Glucophage dose. Buying Glucophage online over the counter. Rx free Glucophage.

[This review was originally posted at the Nieman Journalism Lab Bactrim For Sale, on April 1, 2011.]

Putting the Times' pay plan in place: If you read last week's review, the first half of this week's should feel like déjà vu — lots of back-and-forth about the wisdom of The New York Times' new online pay plan, and some more hand-wringing about getting around that plan. If you want to skip that and get to the best stuff, I recommend Staci Kramer, David Cohn, and Megan Garber.

The Times launched its pay system Monday with a letter to its readers (snarkier version courtesy of Danny Sullivan), along with a 99-cent trial offer for the first four weeks and free access for people who subscribe to the Times on Kindle, Bactrim price. Times digital chief Martin Nisenholtz gave a launch-day talk to newspaper execs, highlighted by his assertion that the link economy is not a win-win for content producers and aggregators.

Meanwhile, the discussion about the paywall's worth rolled on. You can find a good cross-section of opinions in this On Point conversation with Ken Doctor, the Journal Register's John Paton, The Times' David Carr, and NYTClean creator David Hayes, Bactrim For Sale. The plan continues to draw support from some corners, Get Bactrim, including The Onion (in its typically ironic style, of course) and PC Magazine's Lance Ulanoff. Former Financial Times reporter Tom Foremski and Advertising Age columnist Simon Dumenco both made similar arguments about the value of the plan, where can i buy cheapest Bactrim online, with Foremski urging us to support the Times as a moral duty to quality journalism and Dumenco ripping the blogosphere's paywall-bashers for not doing original reporting like the Times.

And though the opposition was expressed much more strongly the past two weeks, there was a smattering of dissent about the plan this week, too — some from the Times' mobile users. One theme among the criticism was the cost of developing the plan: Philip Greenspun wondered how the heck the Times spent $40 million on planning and implementation, and former Guardian digital head Emily Bell wrote about the opportunity cost of that kind of investment. Rx free Bactrim, BNET's Erik Sherman proposed that the Times should have invested the money in innovation instead.

A few other interesting thoughts about the Times' pay plan before we get to the wall-jumping debate: Media consultant Judy Sims said the plan might actually make the Times more social Bactrim For Sale, by providing an incentive for subscribers to share articles on social networks to their non-subscribing friends. Spot.Us' David Cohn argued that the plan is much closer to a donation model than a paywall and argued for the Times to offer membership incentives. And Reuters' Felix Salmon talked about how the proposal is changing blogging at the Times.

PaidContent's Staci Kramer said the Times is fighting an uphill battle in the realm of public perception, but that struggle is the Times' own fault, created by its way-too-complicated pay system.

—

The ethics of paywall jumping: With the Times' "pay fence" going into effect, Bactrim pictures, all the talk about ways to get around that fence turned into a practical reality. Business Insider compiled seven of the methods that have been suggested: A browser extension, Twitter feeds, using different computers, NYTClean and a User Script's coding magic, Google (for five articles a day), and browser-switching or cookie-deleting, Bactrim For Sale. Mashable came up with an even simpler one: delete "?gwh=numbers" from the Times page's URL.

Despite such easy workarounds, the Times is still cracking down in other areas: As Search Engine Land's Danny Sullivan noted, it blocks links from all Google sites after the five-articles-per-day limit is reached. Bactrim price, coupon, The Times also quickly (and successfully) requested a shutdown of one of the more brazen free-riding schemes yet concocted — NYT for a Nickel, which charged to access Times articles without paywall restrictions. (It did, however, let up on unauthorized Twitter aggregators of Times content.)

So we all obviously can crawl through the Times' loopholes, but should we. A few folks made efforts to hack through the ethical thicket of the Times' intentional and unintentional loopholes: Times media critic James Poniewozik didn't come down anywhere solid Bactrim For Sale, , but said the Times' leaky strategy "makes the paywall something like a glorified tip jar, on a massive scale—something you choose to contribute to without compulsion because it is the right thing" — except unlike those enterprises, it's for-profit. In a more philosophical take, the Lab's Megan Garber said the ethical conundrum shows the difficulty of trying to graft the physical world's ethical assumptions onto the digital world.

—

A possible +1 for publishers: Google made a big step in the direction of socially driven search this week with the introduction of +1, purchase Bactrim online, a new feature that allows users to vote up certain search results in actions that are visible to their social network. Here are two good explainers of the feature from TechCrunch and Search Engine Land, both of whom note that +1's gold mine is in allowing Google to personalize ads more closely, and that it's starting on search results and eventually moving to sites across the web.

The feature was immediately compared to Facebook's "Like" and Twitter's retweets, Bactrim no rx, though it functions a bit differently from either. As GigaOM's Mathew Ingram noted, because it's Google, it's intrinsically tied to search, which is both an advantage and a disadvantage. As Ingram said, it's smart to add more of a social component to search, but Google's search-centricity makes the "social network" aspect of +1 awkward, just as Buzz and Wave were, Bactrim For Sale. To paraphrase the argument of Frederic Lardinois of NewsGrange: if your +1's go into your Google Profile and no one sees them, do they really make a sound, generic Bactrim.

All this seems to be good news for media sites. Lost Remote's Cory Bergman said that if they essentially become "improve the SEO of this site" buttons, media companies will be pretty motivated to add them to their sites. Likewise, Poynter's Damon Kiesow reasoned that +1 could be a great way for media sites to more deeply involve visitors who arrive via Google, Bactrim duration, who have typically been less engaged than visitors from Facebook and Twitter.

—

Shrinking innovation to spur it: This month's Carnival of Journalism Bactrim For Sale, focuses on how to drive innovation, specifically through the Knight News Challenge and Reynolds Journalism Institute. Most of the posts rolled in yesterday, and they contain a litany of quick, smart ideas of new directions for news innovation and how to encourage it.

A quick sampling: City University London and Birmingham City University j-prof Paul Bradshaw proposed a much broader, smaller-scale News Challenge fund, with a second fund aimed at making those initiatives scale, where can i buy Bactrim online. J-Lab Jan Schaffer said we need to quit looking at innovation so much solely in terms of tools and more in terms of processes and relationships. British journalist Mary Hamilton and Drury j-prof Jonathan Groves both focused on innovation in training, with Groves proposing "innovation change agents" funded by groups like Knight and the RJI to train and transform newsrooms.

Also, University of British Columbia j-prof Alfred Hermida opined on the role of theory in innovation, Lisa Williams of Placeblogger advocated a small-scale approach to innovation, and the University of Colorado's Steve Outing had some suggestions for the RJI fellowship program, Bactrim For Sale.

—

The mechanics of Twitter's information flow: Four researchers from Yahoo and Cornell released a study this week analyzing, as they called it, Buy Bactrim no prescription, "who says what to whom on Twitter." One of their major findings was that half the information consumed on Twitter comes from a group of 20,000 "elite" users — media companies, celebrities, organizations and bloggers. As Mathew Ingram of GigaOM observed, that indicates that the power law that governs the blogosphere is also in effect on Twitter, and big brands are still important even on a user-directed platform, Bactrim no prescription.

The Lab's Megan Garber noted a few other interesting implications of the study, delving into Twitter's two-step flow from media to a layer of influential sources to the masses, as well as the social media longevity of multimedia and list-oriented articles. A couple of other research-oriented items about Twitter: A Lab post on Dan Zarrella's data regarding timing and Twitter posts, and Maryland prof Zeynep Tufekci wrote a more theoretical post on NPR's Andy Carvin and the process of news production on Twitter.

—

Reading roundup: Plenty of other bits and pieces around the future-of-news world this week:

— New York Times editor Bill Keller wrote a second column Bactrim For Sale, , and like his anti-aggregation piece a couple of weeks ago, this piece — about the value of the Times' impartiality and fact-based reporting — didn't go over well. Buy Bactrim without prescription, Reuters' Felix Salmon called him intellectually dishonest, Scott Rosenberg called him defensive, and the Huffington Post's Peter Goodman (a former Times reporter) said Keller misrepresented him.

— A few notes on The Daily: Forbes' Jeff Bercovici said it was downloaded 500,000 times during its trial period and has 70,000 regular users, and a study was conducted finding that it's more popular with less tech-savvy, purchase Bactrim for sale, less content-concerned users.

— Journal Register Co. CEO John Paton talked about transforming newspapers at the Newspaper Association of America convention; he summarized what he had to say in 10 tweets, and Alan Mutter wrote a post about the panel. The moderator, Ken Doctor, wrote a Lab post looking at how long newspapers have left.

— I'll send you off with Jonathan Stray's thoughtful post on rethinking journalism as a system for informing people, rather than just a series of stories. It's a lot to chew on, but a key piece to add to the future-of-news puzzle.

Similar posts: Buy Tramadol No Prescription. Order Flagyl. Tramadol Over The Counter. Purchase Armour. Cheap Retin A no rx. Purchase Glucophage for sale.
Trackbacks from: Bactrim For Sale. Bactrim For Sale. Bactrim For Sale. Bactrim dosage. Ordering Bactrim online. Buy cheap Bactrim no rx.